---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021958"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:17:55.340078+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics appoints Alex Sapir CEO, reports Q1 net loss of $24.8M, FTX-6058 on clinical hold

## Summary
- Alex Sapir appointed CEO/President effective July 1, 2023; he will serve as special advisor until then.
- Esther Rajavelu resigned as CFO effective Apr 21, 2023; Robert Gould appointed interim principal financial officer.
- FDA placed FTX-6058 for sickle cell disease on full clinical hold in Feb 2023; active discussions ongoing.
- Phase 3 REACH trial of losmapimod in FSHD enrollment on track to complete in second half of 2023.
- Q1 2023 net loss $24.8M; cash, equivalents, and marketable securities $297.8M; cash runway into mid-2025.

## SEC filing metadata
- accession: 0000950170-23-021958
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/fulc-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021958
- JSON: https://secwatch.observer/filing/0000950170-23-021958.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021958.txt

## Key facts
- Earnings Releases
  Fulcrum Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss was $24.8 million.
  - Period: quarter ended March 31, 2023
  - Net income: Net loss was $24.8 million
  - Result: reported results
  source text: Collaboration revenue was $0.3 million for the first quarter of 2023 as compared to $2.6 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
- Earnings Releases
  Fulcrum Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss was $24.8 million.
  - Period: quarter ended March 31, 2023
  - Net income: Net loss was $24.8 million
  - Result: reported results
  source text: Net loss was $24.8 million for the first quarter of 2023 as compared to $25.9 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
- Executive change
  Alex C. Sapir was appointed as President and Chief Executive Officer at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
- Executive change
  Robert E. Gould was appointed as principal financial officer at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: On May 11, 2023, in recognition of the duties he is performing and the vacancy in the chief financial officer position, Fulcrum’s board of directors, or the Board, appointed Robert E. Gould, current interim president and chief executive officer, as principal financial officer, with immediate effect.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
- Executive change
  Robert E. Gould changed role as principal executive officer and principal financial officer at Fulcrum Therapeutics, Inc..
  - Action: succeeded
  - Role: principal executive officer and principal financial officer
  source text: Mr. Sapir will succeed Dr. Gould as principal executive officer and as principal financial officer effective July 1, 2023. Dr. Gould will remain on the Board as a class III director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm
- Executive change
  Alex C. Sapir was appointed as class II director at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: class II director
  source text: On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000095017023021958/0000950170-23-021958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.